Managing Alpha Thalassemia Minor in Deletional Haemoglobin H Disease
Deletional haemoglobin H disease (deletional HbH disease) is a specific subtype of alpha thalassemia that presents a distinct clinical picture. Recognising this scenario early shapes the management approach that follows.
Clinical scenario
Individuals with deletional HbH disease typically have mild, asymptomatic anaemia. The condition often goes unsuspected until an incidental laboratory finding of anaemia prompts diagnostic workup. Despite its generally mild course, targeted clinical follow-up and supplementation are warranted from early in life.
Treatment approach (partial summary)
Management in this setting includes nutritional supplementation started in infancy, with one key vitamin-deficiency status monitored and addressed as needed. The full protocol specifies agents, timing, and monitoring — access it via the link below.
References
Individuals with deletional HbH disease usually have mild asymptomatic anaemia that remains unsuspected in many cases until an incidental laboratory finding of anaemia prompts diagnostic workup.
Folic acid 0.4 to 1 mg per day is recommended to all patients starting around 6 months.
Vitamin D status is checked to maintain sufficiency, using supplements if needed.
View source ↗